Skip to content

Study · Animal study (in vivo) · mouse · 2009

6 results

Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.

Kim S, Moon M, Park S

The Journal of endocrinology1 Jul 2009Cited by 231 (Europe PMC)

PMID19570816 (opens in a new tab)DOI10.1677/joe-09-0132 (opens in a new tab)PepBankPUB-19570816
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In the mouse MPTP model, systemic exendin‑4 attenuated substantia nigra neuron loss.

    In plain wordsIn mice with MPTP injury, exendin‑4 reduced substantia nigra neuron loss compared with injury alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseSNpc neuron loss
    Study

    mousen: not reported in source

    MPTP Parkinson's disease model
    Comparator
    MPTP injury
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    Here, we show that, in the mouse MPTP PD model, systemic administration of exendin-4 significantly attenuates the loss of substantia nigra pars compacta (SNpc) neurons and the striatal dopaminergic fibers.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In the mouse MPTP model, systemic exendin‑4 attenuated striatal dopaminergic fiber loss.

    In plain wordsIn mice with MPTP injury, exendin‑4 reduced dopamine nerve fiber loss compared with injury alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseStriatal dopaminergic fiber loss
    Study

    mousen: not reported in source

    MPTP Parkinson's disease model
    Comparator
    MPTP injury
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    Here, we show that, in the mouse MPTP PD model, systemic administration of exendin-4 significantly attenuates the loss of substantia nigra pars compacta (SNpc) neurons and the striatal dopaminergic fibers.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In the mouse MPTP model, exendin‑4 prevented microglial activation in the substantia nigra and striatum.

    In plain wordsIn mice with MPTP injury, exendin‑4 prevented microglial activation compared with injury alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseMicroglial activation
    Study

    mousen: not reported in source

    MPTP Parkinson's disease model
    Comparator
    MPTP injury
    Outcome group
    Immune response · Nervous system and cognition
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    Exendin-4 prevents MPTP-induced microglial activation in the SNpc and striatum, and the expression of matrix metalloproteinase-3.
    1 context sentence
    Summary · context
    Here, we show that, in the mouse MPTP PD model, systemic administration of exendin-4 significantly attenuates the loss of substantia nigra pars compacta (SNpc) neurons and the striatal dopaminergic fibers.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In the mouse MPTP model, exendin‑4 prevented matrix metalloproteinase-3 expression.

    In plain wordsIn mice with MPTP injury, exendin‑4 prevented matrix metalloproteinase-3 expression compared with injury alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseMatrix metalloproteinase-3 expression
    Study

    mousen: not reported in source

    MPTP Parkinson's disease model
    Comparator
    MPTP injury
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    Exendin-4 prevents MPTP-induced microglial activation in the SNpc and striatum, and the expression of matrix metalloproteinase-3.
    1 context sentence
    Summary · context
    Here, we show that, in the mouse MPTP PD model, systemic administration of exendin-4 significantly attenuates the loss of substantia nigra pars compacta (SNpc) neurons and the striatal dopaminergic fibers.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In the mouse MPTP model, exendin‑4 suppressed tumor necrosis factor alpha expression.

    In plain wordsIn mice with MPTP injury, exendin‑4 reduced tumor necrosis factor alpha expression compared with injury alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseTumor necrosis factor alpha expression
    Study

    mousen: not reported in source

    MPTP Parkinson's disease model
    Comparator
    MPTP injury
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    In addition, exendin-4 also suppressed MPTP-induced expression of pro-inflammatory molecules and tumor necrosis factor alpha and interleukin-1 beta.
    1 context sentence
    Summary · context
    Here, we show that, in the mouse MPTP PD model, systemic administration of exendin-4 significantly attenuates the loss of substantia nigra pars compacta (SNpc) neurons and the striatal dopaminergic fibers.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In the mouse MPTP model, exendin‑4 suppressed interleukin-1 beta expression.

    In plain wordsIn mice with MPTP injury, exendin‑4 reduced interleukin-1 beta expression compared with injury alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseInterleukin-1 beta expression
    Study

    mousen: not reported in source

    MPTP Parkinson's disease model
    Comparator
    MPTP injury
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    In addition, exendin-4 also suppressed MPTP-induced expression of pro-inflammatory molecules and tumor necrosis factor alpha and interleukin-1 beta.
    1 context sentence
    Summary · context
    Here, we show that, in the mouse MPTP PD model, systemic administration of exendin-4 significantly attenuates the loss of substantia nigra pars compacta (SNpc) neurons and the striatal dopaminergic fibers.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.